{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T15:42:49Z","timestamp":1785598969023,"version":"3.56.0"},"reference-count":29,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute of Allergy and Infectious Diseases","award":["75N93022D00005"],"award-info":[{"award-number":["75N93022D00005"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background\/Objectives: Despite progress in antiretroviral therapy, HIV remains a major global health challenge with over one million new infections annually. An effective vaccine is urgently needed. Germline-targeting immunogens show promise in initiating broadly neutralizing antibody (bNAb) precursors. This study developed a scalable, cGMP-compliant process to manufacture the HIV vaccine booster immunogen HxB2.WT.Core-C4b, a nanoparticle designed to direct bNAb precursor maturation after priming. Methods: A CHO cell platform was established through single-cell cloning from a high-producing stable pool. Upstream and downstream processes were optimized for scalability and yield. Three scales were tested 10 L, 40 L, and 400 L. Key parameters (pH, temperature, feeding, metabolite profiles) were systematically refined. Analytical characterization included glycosylation profiling, electron microscopy, and antigenicity testing. Viral clearance was evaluated per ICH Q5A guidelines. Results: Optimization ensured consistent yields above 130 mg\/L, with titers up to 250 mg\/L. The selected clone (4E22) demonstrated strong growth, viability, and reproducibility. Glycan occupancy at 18 N-linked sites, including bNAb epitopes (N276, N332), was stable across scales. Over 70% of self-assembling nanoparticle were fully assembled at the GMP level. Antigenicity and purity met cGMP release criteria. Viral clearance achieved &gt;13-log reduction for enveloped and &gt;7-log for non-enveloped viruses. Conclusions: This work establishes a robust, scalable platform for HIV nanoparticle immunogens. Consistent quality and yield across scales support clinical development of HxB2.WT.Core-C4b and provide a model for other glycosylated nanoparticle vaccines. The immunogen is being evaluated in clinical study HVTN 320 (NCT06796686), enabling early testing of next-generation vaccines designed to elicit broadly neutralizing antibodies.<\/jats:p>","DOI":"10.3390\/vaccines13090980","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T12:54:26Z","timestamp":1758200066000},"page":"980","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["GMP Manufacturing and Characterization of the HIV Booster Immunogen HxB2.WT.Core-C4b for Germline Targeting Vaccine Strategies"],"prefix":"10.3390","volume":"13","author":[{"given":"Sammaiah","family":"Pallerla","sequence":"first","affiliation":[{"name":"IAVI, 125 Broad Street, 9th Floor, New York, NY 10004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4998-3913","authenticated-orcid":false,"given":"Latha","family":"Kallur Siddaramaiah","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, 1100 Fairview Ave. N., Seattle, WA 98109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9095-5657","authenticated-orcid":false,"given":"Philipp","family":"Mundsperger","sequence":"additional","affiliation":[{"name":"Polymun Scientific Immunbiologische Forschung GmbH, Donaustr. 99, 3400 Klosterneuburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0536-3148","authenticated-orcid":false,"given":"Dietmar","family":"Katinger","sequence":"additional","affiliation":[{"name":"Polymun Scientific Immunbiologische Forschung GmbH, Donaustr. 99, 3400 Klosterneuburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Fauland","sequence":"additional","affiliation":[{"name":"Polymun Scientific Immunbiologische Forschung GmbH, Donaustr. 99, 3400 Klosterneuburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Kreismayr","sequence":"additional","affiliation":[{"name":"Polymun Scientific Immunbiologische Forschung GmbH, Donaustr. 99, 3400 Klosterneuburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Weik","sequence":"additional","affiliation":[{"name":"Polymun Scientific Immunbiologische Forschung GmbH, Donaustr. 99, 3400 Klosterneuburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur","family":"Arslan","sequence":"additional","affiliation":[{"name":"Polymun Scientific Immunbiologische Forschung GmbH, Donaustr. 99, 3400 Klosterneuburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingchao","family":"Shen","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, 1100 Fairview Ave. N., Seattle, WA 98109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Ozorowski","sequence":"additional","affiliation":[{"name":"Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hsin","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7153-3769","authenticated-orcid":false,"given":"Andrew B.","family":"Ward","sequence":"additional","affiliation":[{"name":"Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabyasachi","family":"Baboo","sequence":"additional","affiliation":[{"name":"Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolene K.","family":"Diedrich","sequence":"additional","affiliation":[{"name":"Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"John R.","family":"Yates","sequence":"additional","affiliation":[{"name":"Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4589-5322","authenticated-orcid":false,"given":"James C.","family":"Paulson","sequence":"additional","affiliation":[{"name":"Department Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Blumen","sequence":"additional","affiliation":[{"name":"IAVI, 125 Broad Street, 9th Floor, New York, NY 10004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Craig","sequence":"additional","affiliation":[{"name":"IAVI, 125 Broad Street, 9th Floor, New York, NY 10004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Swoyer","sequence":"additional","affiliation":[{"name":"IAVI, 125 Broad Street, 9th Floor, New York, NY 10004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoli","family":"Yuan","sequence":"additional","affiliation":[{"name":"IAVI, 125 Broad Street, 9th Floor, New York, NY 10004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas","family":"Stamatatos","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, 1100 Fairview Ave. N., Seattle, WA 98109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"ref_1","unstructured":"UNAIDS (2024). Global HIV & AIDS Statistics\u2014Fact Sheet, UNAIDS."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(13)61809-7","article-title":"The end of AIDS: HIV infection as a chronic disease","volume":"382","author":"Deeks","year":"2016","journal-title":"Lancet"},{"key":"ref_3","first-page":"399","article-title":"HIV vaccine development: Progress and future challenges","volume":"48","author":"Barouch","year":"2018","journal-title":"Immunity"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014A new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Timofeeva, A., Sedykh, S., and Nevinsky, G. (2022). Post-Immune Antibodies in HIV-1 Infection in the Context of Vaccine Development: A Variety of Biological Functions and Catalytic Activities. Vaccines, 10.","DOI":"10.3390\/vaccines10030384"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1126\/science.aac5894","article-title":"Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen","volume":"349","author":"Jardine","year":"2015","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1126\/science.aad9195","article-title":"HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen","volume":"351","author":"Jardine","year":"2016","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1084\/jem.20161160","article-title":"Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo","volume":"214","author":"Garces","year":"2017","journal-title":"J. Exp. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"10618","DOI":"10.1038\/ncomms10618","article-title":"Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice","volume":"7","author":"McGuire","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1016\/j.celrep.2019.10.071","article-title":"Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization","volume":"29","author":"Parks","year":"2019","journal-title":"Cell Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"105473","DOI":"10.1016\/j.isci.2022.105473","article-title":"Adjuvants influence the maturation of VRC01-like antibodies during immunization","volume":"25","author":"Knudsen","year":"2022","journal-title":"iScience"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e0074424","DOI":"10.1128\/jvi.00744-24","article-title":"Short CDRL1 in intermediate VRC01-like mAbs is not sufficient to overcome key glycan barriers on HIV-1 Env","volume":"98","author":"Agrawal","year":"2024","journal-title":"J. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/imr.12483","article-title":"Germline targeting immunogens","volume":"275","author":"Stamatatos","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Stamatatos, L. (2025). The Germline Targeting Vaccine Concept: Overview and Updates from HIV Pre-clinical and Clinical Trials. Curr. HIV Res.","DOI":"10.2174\/011570162X358302250206074255"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nmat2960","article-title":"Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses","volume":"10","author":"Moon","year":"2012","journal-title":"Nat. Mater."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.coviro.2013.05.010","article-title":"Advances in structure-based vaccine design","volume":"3","author":"Kulp","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Freund, N.T., Horwitz, J.A., Nogueira, L., Sievers, S.A., Scharf, L., Scheid, J.F., Gazumyan, A., Liu, C., Velinzon, K., and Goldenthal, A. (2015). A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1005238"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jsb.2005.03.010","article-title":"Automated molecular microscopy: The new Leginon system","volume":"151","author":"Suloway","year":"2005","journal-title":"J. Struct. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jsb.2009.01.002","article-title":"Appion: An integrated, database-driven pipeline to facilitate EM image processing","volume":"166","author":"Lander","year":"2009","journal-title":"J. Struct. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e42166","DOI":"10.7554\/eLife.42166","article-title":"New tools for automated high-resolution cryo-EM structure determination in RELION-3","volume":"7","author":"Zivanov","year":"2018","journal-title":"eLife"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nmeth.4169","article-title":"cryoSPARC: Algorithms for rapid unsupervised cryo-EM structure determination.","volume":"14","author":"Rubinstein","year":"2017","journal-title":"Nat Methods"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"13651","DOI":"10.1021\/acs.analchem.1c03059","article-title":"DeGlyPHER: An Ultrasensitive Method for the Analysis of Viral Spike N-Glycoforms","volume":"93","author":"Baboo","year":"2021","journal-title":"Anal. Chem."},{"key":"ref_23","unstructured":"Arslan, O., Weik, R., Mundsperger, P., Scientific, P., Pallerla, S., Craig, D., Swoyer, R., and Blumen, T. Research Explores Alternative to EU-Banned Triton X-100. Available online: https:\/\/www.bioprocessonline.com\/doc\/research-explores-alternative-to-eu-banned-triton-x-0001."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1126\/science.1192819","article-title":"Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01","volume":"329","author":"Zhou","year":"2010","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Walker, L.M., Simek, M.D., Priddy, F., Gach, J.S., Wagner, D., Zwick, M.B., Phogat, S.K., Poignard, P., and Burton, D.R. (2010). A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog, 6.","DOI":"10.1371\/journal.ppat.1001028"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jmb.2012.12.017","article-title":"Arranged sevenfold: Structural insights into the C-terminal oligomerization domain of human C4b-binding protein","volume":"425","author":"Hofmeyer","year":"2013","journal-title":"J Mol Biol"},{"key":"ref_27","unstructured":"ICH (1999). ICH Q6B: Specifications: Test Procedures and Acceptance Criteria for Biotechnological\/Biological Products."},{"key":"ref_28","unstructured":"FDA (2008). Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing\u2014Current Good Manufacturing Practice."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s12247-015-9215-8","article-title":"Modernizing pharmaceutical manufacturing: From batch to continuous production","volume":"10","author":"Lee","year":"2015","journal-title":"J. Pharm. Innov."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/9\/980\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:47:32Z","timestamp":1760035652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/9\/980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["vaccines13090980"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13090980","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]}}}